AstraZeneca Regulatory Upgrade on Seroquel XR for the treating Major Depressive Disorder AstraZeneca today announced that the business has referred its program for SEROQUEL XR Extended Launch Tablets for the treating recurrent depressive episodes in adult sufferers with main depressive disorder to the Committee for Medicinal Items for Human Make use of . This comes after notification to AstraZeneca by holland Wellness Authority , acting because the Reference Member Condition for the Mutual Reputation Procedure , that the SEROQUEL XR software for MDD offers been refused. AstraZeneca believes that outcomes from the scientific trial program demonstrate that SEROQUEL XR provides potential as a very important treatment option for sufferers with MDD http://cytoxan.net/ .
AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes AstraZeneca today announced that it has entered right into a five-year analysis collaboration with the Harvard Stem Cell Institute to adapt a method that creates individual beta cells from stem cells for make use of in displays of AstraZeneca’s substance library in the seek out new remedies for diabetes. The collaboration also aims to raised know how the function of beta cells declines in diabetes and study findings will be produced open to the broader scientific community through peer-examined publications. In people who have Type 1 diabetes, beta cells are destroyed by an autoimmune response and individuals must inject insulin to keep normal blood sugar levels.